Retatrutide Liver Research

The anchor publication is the Phase 2 obesity trial from Jastreboff and colleagues, published in the New England Journal of Medicine in 2023. Headline result: participants on the 12mg weekly dose averaged 28.3% body-weight loss at 80 weeks in Phase 3 TRIUMPH-1, the largest figure published for any compound in the incretin class at the time. That number is why retatrutide dominates the research conversation, and it is the context for everything reported about the liver.

I keep the table deliberately short. A research report earns trust by listing only what the record supports, and the record on retatrutide and the liver is one Phase 2 cohort deep.

Within the Phase 2 program, a cohort of participants with MASLD, metabolic dysfunction-associated steatotic liver disease, the condition formerly filed under non-alcoholic fatty liver disease, had their liver fat measured over the trial. The published finding: large reductions in liver-fat content across the treatment period. I am not quoting a specific percentage here because I hold this site to the figures I have verified against the publications I cite, and the honest summary of this cohort is directional and strong rather than a single clean number.

Why researchers found it notable: liver fat is a metabolic endpoint that does not always move in proportion to body weight, and a compound producing outsized movement on it invites mechanistic questions. That is precisely the kind of signal Phase 3 programs exist to confirm or deflate, and TRIUMPH is running now.

Retatrutide is a triple agonist: GLP-1, GIP, and glucagon receptors. The first two are the appetite-and-insulin axis shared with semaglutide and tirzepatide. The third is the differentiator: glucagon receptor activation, pulsed chronically through a peptide drug, activates hepatic fat oxidation and shifts the body toward burning stored fat as fuel. The liver is where that mechanism physically operates, which is why a liver-fat signal in the retatrutide data is mechanistically coherent rather than a statistical curiosity.

Coherent is not the same as proven. The mechanism story explains why the Phase 2 finding is plausible; only the Phase 3 record can establish what it is worth. The full compound picture, dosing patterns in the research literature, and side-effect profile live on the retatrutide dossier.

A short list, because this is where research reporting usually goes wrong. The published data does not say retatrutide treats fatty liver disease. It does not say liver-fat reduction translates into improved liver outcomes, which is a separate endpoint requiring years of follow-up. It does not cover people with advanced fibrosis or cirrhosis. And it says nothing about research-grade material bought outside a trial, which is manufactured, handled, and dosed under none of the controls that produced the published numbers.

There is no approved retatrutide product in the Philippines and no pharmacy will sell you one at any price. What exists is the research-grade vial market: 10mg vials at ₱5,500 to 8,500 and 30mg bulk vials at ₱14,500 to 19,500 from suppliers with COA documentation, shipped by insulated courier with cold packs, 1 to 3 days nationwide. Metro Manila has same-day courier options; outside it, ordering online is the only route, since research-peptide retail is effectively zero in provincial cities. The sourcing mechanics, customs reality, and supplier red flags are catalogued in the retatrutide Philippines guide.